Close Menu

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Horizon Discover today said it is collaborating with the Rosalind Franklin University of Medical Sciences to develop a human cellular disease model of cystic fibrosis.

The deal covers use of Horizon's Genesis precision genome editing technology to "reconstitute a specific mutation" in the cystic fibrosis transmembrane conductance regulator, or CFTR, protein in the endogenous genome of a lung cancer cell line.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.

US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.

Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.

In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.

Aug
28
Sponsored by
Horizon Discovery

This webinar will provide an overview of alternatives to the popular Cas9 nuclease used in CRISPR gene editing.